Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B‑type natriuretic peptide levels

Yuan,Jiangshui; Li,Li; Wang,Zhaoyan; Song,Weiqing; Zhang,Zongliang

doi:10.3892/br.2015.544

Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B‑type natriuretic peptide levels

Authors:
- Jiangshui Yuan
- Li Li
- Zhaoyan Wang
- Weiqing Song
- Zongliang Zhang
View Affiliations

Affiliations: Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China, Department of Urology, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China
Published online on: November 18, 2015 https://doi.org/10.3892/br.2015.544
Pages: 68-72

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the association between the levels of lipids and B‑type natriuretic peptide (BNP) in systemic lupus erythematosus (SLE) patients with heart failure (HF). A total of 46 patients with active SLE and 40 healthy, age‑matched control subjects were studied. BNP was measured by an immunofluorescence assay in fresh plasma. Total cholesterol (TC), triglycerides (TG), high‑density lipoprotein cholesterol (HDL‑C), low‑density lipoprotein cholesterol, apolipoprotein (Apo) B, ApoA‑I and lipoprotein(a) were assessed. Compared with the control subjects, HDL‑C and ApoA‑I levels were considerably decreased and TG level increased markedly from SLE patients. The average concentration of HDL‑C and ApoA‑I in the SLE group with HF was significantly reduced compared to those patients without HF. The results showed that the levels of HDL‑C and ApoA‑I in SLE patients were negatively correlated with BNP. Disease activity was associated with the TC and TG levels. The present data indicated the presence of a cardiovascular (CV) risk in active SLE with high disease activity, which was demonstrated by the high frequency of dyslipidemia and higher BNP concentrations. Therefore, dyslipoproteinemia may underlie some of the increased risk for CV disease and HF in patients with SLE.

View Figures

View References

1	Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, et al: Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 12:1004–1015. 2013. View Article : Google Scholar : PubMed/NCBI
2	Nikpour M, Urowitz MB, Ibañez D and Gladman DD: Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 61:1152–1158. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gaggin HK and Januzzi JL Jr: Natriuretic peptides in heart failure and acute coronary syndrome. Clin Lab Med. 34:43–58. 2014. View Article : Google Scholar : PubMed/NCBI
4	Gaggin HK and Januzzi JL Jr: Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 1832:2442–2450. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
6	Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A, Bloch DA, Corey PN, Decker JL, et al: The Committee on Prognosis Studies in SLE: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 35:630–640. 1992. View Article : Google Scholar : PubMed/NCBI
7	Ye Y, Wang Y and Shen Z: National Guide to Clinical Laboratory Procedures of China. (3rd). Medical Administration Department of Ministry of Public Health (China). 2006.
8	Aranow C and Ginzler EM: Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus. 9:166–169. 2000. View Article : Google Scholar : PubMed/NCBI
9	Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP and Kuller LH: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42:51–60. 1999. View Article : Google Scholar : PubMed/NCBI
10	Ammirati E, Moroni F, Pedrotti P, Scotti I, Magnoni M, Bozzolo EP, Rimoldi OE and Camici PG: Non-invasive imaging of vascular inflammation. Front Immunol. 5:3992014. View Article : Google Scholar : PubMed/NCBI
11	Bruce IN, Gladman DD and Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 26:257–278. 2000. View Article : Google Scholar : PubMed/NCBI
12	Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, et al: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44:2331–2337. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F and Meroni PL: Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 73:609–615. 2014. View Article : Google Scholar : PubMed/NCBI
14	Symmons DP and Gabriel SE: Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 7:399–408. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN and Espiner EA: Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf). 47:287–296. 1997. View Article : Google Scholar : PubMed/NCBI
16	Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski K, Ilowite NT, von Scheven E, Eberhard A, Levy DM, et al: APPLE investigators: Laboratory markers of cardiovascular risk in pediatric SLE: The APPLE baseline cohort. Lupus. 19:1315–1325. 2010. View Article : Google Scholar : PubMed/NCBI
17	Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL and von Scheven E: Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 51:451–457. 2004. View Article : Google Scholar : PubMed/NCBI
18	Posadas-Romero C, Torres-Tamayo M, Zamora-González J, Aguilar-Herrera BE, Posadas-Sánchez R, Cardoso-Saldaña G, de Guevara Ladrón G, Solis-Vallejo E and El Hafidi M: High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum. 50:160–165. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lilleby V, Haugen M, Mørkrid L, Frey Frøslie K, Holven KB and Førre O: Body composition, lipid and lipoprotein levels in childhood-onset systemic lupus erythematosus. Scand J Rheumatol. 36:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tyrrell PN, Beyene J, Benseler SM, Sarkissian T and Silverman ED: Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol. 34:2112–2119. 2007.PubMed/NCBI
21	Borba EF and Bonfá E: Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus. 6:533–539. 1997. View Article : Google Scholar : PubMed/NCBI
22	Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM and Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:882–888. 1996. View Article : Google Scholar : PubMed/NCBI
23	Ilowite NT, Samuel P, Ginzler E and Jacobson MS: Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum. 31:859–863. 1988. View Article : Google Scholar : PubMed/NCBI
24	Beaumont JL and Beaumont V: Autoimmune hyperlipidemia. Atherosclerosis. 26:405–418. 1977. View Article : Google Scholar : PubMed/NCBI